Eubel Brady & Suttman Asset Management Inc. Invests $1.25 Million in Amgen Inc. $AMGN

Eubel Brady & Suttman Asset Management Inc. purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,416 shares of the medical research company’s stock, valued at approximately $1,246,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC lifted its stake in shares of Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares in the last quarter. Norges Bank acquired a new stake in Amgen in the 2nd quarter valued at about $1,663,726,000. Vanguard Group Inc. raised its holdings in Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after acquiring an additional 841,117 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares in the last quarter. Finally, Mizuho Markets Cayman LP acquired a new position in shares of Amgen during the 2nd quarter worth approximately $135,597,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Guggenheim increased their price target on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Leerink Partners raised their target price on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. DZ Bank upped their price objective on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Wells Fargo & Company lifted their target price on shares of Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average target price of $354.04.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.76% of the company’s stock.

Amgen Trading Up 0.5%

Shares of AMGN stock opened at $366.58 on Thursday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The firm has a market cap of $197.40 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 3.73 and a beta of 0.46. The company has a 50-day moving average of $336.16 and a two-hundred day moving average of $312.77. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 66.90%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Daiwa raised its price target to $410 and kept an “outperform” rating, signaling meaningful upside versus recent levels. Daiwa target raise
• Positive Sentiment: Fundamental tailwinds: Amgen recently beat EPS and revenue expectations and set FY2026 EPS guidance (21.60–23.00), which supports near-term confidence in earnings power and helped lift sentiment. (Company earnings release)
• Neutral Sentiment: Zacks published a momentum-themed piece highlighting AMGN as a top-ranked momentum stock — useful for momentum investors but not a direct catalyst. Zacks momentum article
• Neutral Sentiment: Brokerage consensus remains constructive (reported as “Moderate Buy”), which is supportive but largely confirms existing analyst views. Consensus rating
• Neutral Sentiment: Amgen will trade ex-dividend in two days — a routine liquidity/event timing item that can briefly affect intraday moves but is not a fundamental change. Ex-dividend notice
• Neutral Sentiment: Recent short-interest reports show zero shares and NaN changes — this appears to be erroneous or non-actionable data, so it shouldn’t be driving meaningful market moves today.
• Negative Sentiment: Mizuho raised its target from $280 to $295 but that target still implies a material downside relative to recent market levels, which could temper upside expectations despite the upgrade. Mizuho target note

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.